Clinical trial
Combination Chemotherapy and Alemtuzumab in Treating Patients With Relapsed or…
NCT00262925 · National Cancer Institute (NCI), NIH · Terminated
Key facts
| NCT number | NCT00262925 |
|---|---|
| Title | Combination Chemotherapy and Alemtuzumab in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia |
| Official title | A Phase II Study of MOAD (Methotrexate, Vincristine, L-asparaginase and Dexamethasone) With Subcutaneous Campath for Adults With Relapsed or Refractory Acute Leukemia (ALL) |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Adult Acute Lymphoblastic Leukemia |
| Intervention type | Biological, Drug |
| Interventions | alemtuzumab, asparaginase, methotrexate, dexamethasone, leucovorin calcium, mercaptopurine, vincristine |
| Enrollment | 12 |
| Start date | Jun 1, 2006 |
| Primary completion | Oct 1, 2012 |
| Completion | Feb 1, 2013 |
| First posted | Dec 7, 2005 |
| Last update posted | May 5, 2015 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: